Skip to content

General Information for Sponsors and Vendors

Exhibitor Space at Capacity: no more tabletops available

Venom Week symposiums could not take place without the support of our Sponsors listed below.
Exhibit suite will be located adjacent to the lecture room.  Exhibit suite has private conference room for meetings with attendees.

Company Exhibitors will be located in
Skysong Center
Bldg 3 – ThinkZilla Suite
1475 N. Scottsdale Rd
Scottsdale, Arizona 85257

Educational Exhibits will be located in
Skysong Center
Bldg 3 – Synergy Room
1475 N. Scottsdale Rd
Scottsdale, Arizona 85257

Exhibitors will be available to access the space on Sunday July 17th, from 2pm-4pm; or Monday July 19th from 6am-8am.
This building will be locked each night.
Please contact Avery Bender at or by cell at 352-328-7506 with any questions regarding set up.


Rare Disease Therapeutics, Inc. (RDT) is America’s first exclusively orphan drug company committed to developing and marketing drugs for rare disorders. RDT is dedicated to patients with unmet medical needs including envenomations. RDT and Laboratorios Silanes, S.A. de C.V. have a joint development and distribution agreement for F(ab’)₂ antivenoms.  Silanes, founded in 1943, is a world leader in the development and marketing of antivenom for snake, scorpion, and spider envenomation on three continents.


Ophirex, Inc. is a Public Benefit Corporation focused on antidotes for acute life- threatening toxidromes such as snakebite envenoming. We are committed to addressing the medical needs associated with snakebite and other life-threatening diseases and conditions with common mechanisms of illness and injury. Presently, we are focused on developing an affordable, accessible, oral treatment for snakebite envenoming. Our lead drug candidate, varespladib, blocks sPLA2, a prevalent, highly toxic component of venom found in at least 95% of snake venom types. Varespladib is intended for worldwide human and veterinary use, with an oral formulation for use in the field, where most bites occur, and an intravenous formulation for use in medical settings for situations where it might be preferable to the oral formulation (e.g. vomiting or unstable patients). By making such a treatments available, we hope to substantially reduce morbidity and mortality of snakebite, as well as provide enormous savings to individual patients and healthcare systems.  The concept for developing small molecule antidotes became reality when Dr. Lewin met Mr. Jerry Harrison, a renowned musician and successful entrepreneur best known for his membership in the Modern Lovers and the Talking Heads. With additional support from family and friends, the two launched Ophirex and joined forces with global leaders working to raise awareness of snakebite as a neglected tropical disease. Dr. Lewin serves as Chief Scientific Officer of Ophirex and, as well, Director for the Center for Exploration and Travel Health at the California Academy of Sciences in San Francisco. He is Board Certified in Emergency Medicine and is a member of the WHO Snakebite Envenoming Working Group

The Institute for Future Health (IFH) is a joint venture between Arizona State University and the University of Arizona.  The IFH serves as a centralized hub for multi-disciplinary healthcare research across Arizona’s public academic institutions.


Inosan Biopharma is a biotech company with 10 years of experience. We are dedicated to the development of antibodies for several applications as antivenoms, antitoxins and antivirals. We are committed to scientific innovation with the goals of constant improvement and helping people and communities affected by neglected and emergent diseases

Educational Sponsor